COLL Collegium Pharmaceutical, Inc.
Healthcare$33.78-0.85%ClosedMarket Cap: $1.10B
As of 2026-05-26
Valuation
P/E (TTM)
17.91
PEG
—
P/B
3.50
P/S
1.39
EV/EBITDA
2.71
DCF Value
$634.78
FCF Yield
29.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
60.7%
Operating Margin
23.8%
Net Margin
9.4%
ROE
26.7%
ROA
4.5%
ROIC
10.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $193.5M | 60.6% | $32.0M | $14.5M | $— | — |
| Q4 null | $205.4M | 62.5% | $59.2M | $17.0M | $— | — |
| FY null | $780.6M | 59.3% | $187.1M | $62.9M | $— | — |
| Q3 null | $209.4M | 61.7% | $63.6M | $31.5M | $— | — |
| Q2 null | $188.0M | 57.7% | $35.1M | $12.0M | $— | — |
| Q1 null | $177.8M | 54.8% | $21.7M | $2.4M | $— | — |
| Q4 null | $181.9M | 54.0% | $38.1M | $12.5M | $— | — |
| FY null | $631.4M | 59.8% | $169.9M | $69.2M | $— | — |
| Q3 null | $159.3M | 60.8% | $34.8M | $9.3M | $— | — |
| Q2 null | $145.3M | 62.5% | $47.5M | $19.6M | $— | — |
| Q1 null | $144.9M | 63.1% | $49.5M | $27.7M | $— | — |
| Q4 2023 | $149.7M | 63.2% | $61.7M | $31.9M | $0.82 | — |